




The relative strengths and weaknesses of Ernexa Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ernexa Therapeutics Inc compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 55% points. The greatest weakness of Ernexa Therapeutics Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 115% points.

The company's Economic Capital Ratio, given in the ranking table, is 140%, being 73% points below the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	9,599
Cost of Goods Sold	236
Intangible Assets	2,044
Liabilities, Current	6,573
Liabilities, Non-Current	32,854
Other Assets	36,996
Other Compr. Net Income	0
Other Expenses	457
Other Liabilities	7,472
Other Net Income	-536
Other Revenues	68
Property and Equipment	493
Research and Development	5,920
Selling, General and Administrative Expense	14,587

Output Variable	Value in 1000 USD
Assets	49,132
Liabilities	46,899
Expenses	21,200
Revenues	68
Stockholders Equity	2,233
Net Income	-21,668
Comprehensive Net Income	-21,668
BaseVar	58,918
ECR before LimitedLiability	-35%
Economic Capital Ratio	140%